Professor David Nutt Joins AWAKN Life Sciences

Professor David Nutt Joins AWAKN Life Sciences

Professor David Nutt is a world renowned neuroscientist, leading global authority on drug policy reform and former chief drug advisor to the UK government.

AWAKN Life Sciences Inc. (“AWAKN”) is pleased to announce the appointment of Professor David Nutt as Chairman of its newly formed Scientific Advisory Board (SAB).

Professor David Nutt is a world renowned neuroscientist, leading global authority on drug policy reform and former chief drug advisor to the UK government. He serves as the Edmond J. Safra Professor of Neuropsychopharmacology and director of the neuropsychopharmacology unit in the Division of Brain Sciences at Imperial College London, and Founding Chair of Drug Science (formerly the Independent Scientific Committee on Drugs).

AWAKN’s SAB will provide strategic scientific counsel as the company implements its vision and strategy across three business lines of clinical research, therapeutic clinics and healthcare training.

Dr. Ben Sessa, AWAKN Chief Medical Officer, stated: “David has always been a trailblazer and supporter of innovative psychopharmacology. He is a prolific promoter of drug reform policies and an internationally respected scientific researcher. I have had the pleasure of working alongside David on numerous psychedelic studies over the last 10 years, and we know the time is right and the time is now. David shares AWAKN’s vision of how clinical psychedelics in combination with psychotherapy can cure mental health conditions. This is a new way of doing psychiatry. This is the medicine of the future.”

Prof. David Nutt, AWAKN Scientific Advisory Board Chair, stated: “I am delighted to be able to support this exciting initiative. I believe psychedelic treatments have the opportunity to change psychiatry in the way immunotherapies are changing medicine. The sooner we can start using these the better it will be for patients, and I am pleased AWAKN are taking the lead in this.”

Anthony Tennyson, AWAKN CEO, stated: “What a time this is for psychedelic medicine. An era of scientific and therapeutic innovation with real potential to move the dial on mental health care. Professor Nutt encapsulates the essence of scientific change, and we are honored to welcome such global pedigree to the mix alongside his longtime friend and collaborator, our Chief Medical Officer, Dr. Ben Sessa.”

About Professor David Nutt

Prof. David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit in the Division of Brain Sciences.

After 11+ entry to Bristol Grammar School David was awarded an Open Scholarship to Downing College Cambridge and then completed his medical training at Guy’s Hospital London, continuing in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET.

David is currently Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD)). He was previously President of the European Brain Council, the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA) and the British Association of Psychopharmacology (BAP). He is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over two decades and acts as the psychiatry drugs advisor to the British National Formulary. He has published over 500 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 33 books.

Previously he has been a member and then Chair of the Advisory Committee on the Misuse of Drugs (ACMD – 1998-2009), a member of the HEFCE/NHS Senior Lecturer Selection Panel and of the MRC Neuroscience Board. Other previous national contributions include serving as the medical expert on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS drugs and the Ministry of Defence Science Advisory Board. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that provided a 25-year vision for this area of science and public policy.

David broadcasts widely to the general public both on radio and television including BBC science and public affairs programmes on therapeutic as well as illicit drugs, their harms and their classification. He also lectures widely to the public as well as to the scientific and medical communities; for instance has presented three times at the Cheltenham Science Festival and several times for Café Scientifiques. In 2010 The Times Eureka science magazine included him in the 100 most important figures in British Science, and the only psychiatrist.

About AWAKN Life Sciences

AWAKN Life Sciences Inc. provides evidence-based Psychedelic Assisted Psychotherapy solutions to heal mental health conditions. We work across three business lines of clinical research, therapeutic clinics and healthcare training. Our focus is ensuring optimal patient safety, while delivering efficacy through transformative patient care, in conjunction with scientifically validating long-term mental health.

Source

Hastings Technology Metals Ltd Stand-out Simon’s Find Metallurgical Test Results Amended

Perth, Australia (ABN Newswire) – Australia’s next rare earths producer Hastings Technology Metals Ltd (ASX:HAS) (5AM.F) is pleased to announce stand-out results from metallurgical test work carried out on drilling samples from Simon’s Find, one of the key deposits that make up the Yangibana Rare Earths Project (Yangibana) in Western Australia’s Gascoyne region.

The test work carried out at Simon’s Find is a key milestone in the Company’s finalisation of its updated Ore Reserves and mine scheduling that will underpin Yangibana’s development.

The Simon’s Find deposit is part of the 8km-long Bald Hill – Simon’s Find – Frasers mineralised trend and is strategically located close to the site of Yangibana’s proposed process plant and infrastructure.

Keep reading... Show less

Rio Tinto and ARENA to study using hydrogen to reduce carbon emissions in alumina refining

Rio Tinto has partnered with the Australian Renewable Energy Agency (ARENA) to study whether hydrogen can replace natural gas in alumina refineries to reduce emissions.

Rio Tinto will conduct a $1.2 million feasibility study, equally funded with ARENA through a $580,000 grant, into using clean hydrogen to replace natural gas in the calcination process of refining at the Yarwun aumina refinery in Gladstone.

Keep reading... Show less

ASX Rare Earths Stocks

Rare earths are a group of commodities that Australia has done well to corner the market on, not because of a monopoly on resources (indeed Australia only accounts for 3 percent of global reserves), but because it was ahead of the curve when it comes to investment.

The story of rare earths in Australia — the modern success story at least — has its roots in a 2010 trade dispute between Japan and China, when China throttled exports of rare earths to Japan as retribution for a fisheries clash.

Long story short, Japan found itself looking to diversify its rare earths import partners. Up until then it had been beholden to the whims of its larger neighbour, which at the time accounted for over 93 percent of rare earths output.

Keep reading... Show less

Phase 2 Drilling Progress Update – Clarification Announcement

European Lithium Limited (ASX: EUR, FRA: PF8,) (European Lithium or the Company) wishes to provide a clarification to its announcements released on 3 June 2021 and 10 June 2021 in relation in relation to the Phase 2 resource extension drilling program at the Wolfsberg Lithium Project (Wolfsberg or Project).


Keep reading... Show less

Galena Makes Final Investment Decision for Abra

GALENA MINING LTD. (ASX:G1A) announces that Abra Mining Pty Limited ("AMPL"), the joint-venture company for the Abra Base Metals Project ("Abra" or the "Project") has made the final investment decision ("FID") to complete the full development of Abra, with first production of its high-value, high-grade lead-silver concentrate scheduled for the first quarter of 2023 calendar year. The FID decision has been made following the satisfaction of key conditions to draw in excess of US$30 million under the Taurus Debt Facilities.


Keep reading... Show less

Hastings Technology Metals Ltd Stand-Out Simon’s Find Metallurgical Test Results

Perth, Australia (ABN Newswire) – Australia's next rare earths producer Hastings Technology Metals Ltd (ASX:HAS) is pleased to announce stand-out results from metallurgical test work carried out on drilling samples from Simon's Find, one of the key deposits that make up the Yangibana Rare Earths Project (Yangibana) in Western Australia's Gascoyne region.

The test work carried out at Simon's Find is a key milestone in the Company's finalisation of its updated Ore Reserves and mine scheduling that will underpin Yangibana's development.

Keep reading... Show less

Top News

Related News